Takeda (TAK) Insider to Sell 4,477 ADSs Worth $69K – Form 144

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) has filed a Form 144 indicating a proposed sale of restricted securities.

• Securities to be sold: 4,477 American Depositary Shares (ADSs).
• Estimated market value: US $69,035.34.
• Broker: Interactive Brokers LLC, Greenwich, CT.
• Approximate sale date: 9 July 2025 on the NYSE.
• Shares outstanding: 123,490,548 ADSs – the planned sale represents less than 0.01% of this total.
• Source of shares: Vested Restricted Stock Unit (RSU) awards acquired 1 July 2025 as compensation from Takeda Pharmaceutical Company Limited.
• Prior sales: None reported in the past three months.

The filing is routine and does not include earnings data or announce any strategic transactions. It simply registers a modest insider sale that is immaterial relative to the company’s share base.

Insights

Securities Analyst

TL;DR: Small insider Form 144 for 4,477 ADSs (US$69k) is routine and immaterial; no strategic signal for TAK investors.

The notice covers a proposed sale amounting to roughly 0.004% of Takeda’s ADS float. Such filings are common for employees or executives monetising vested RSUs. The aggregate value is negligible for a US$50 billion-plus market-cap company and does not alter supply–demand dynamics. No adverse information is asserted in the certification, and no additional sales have occurred in the prior quarter. I view the disclosure as non-impactful to the investment thesis or valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Takeda (TAK) ADSs are being sold under this Form 144?

The filing covers 4,477 ADSs.

What is the approximate market value of the proposed TAK share sale?

The aggregate market value is US$69,035.34.

When is the expected sale date for the Takeda ADSs?

The filer plans to sell on or about 9 July 2025.

What percentage of Takeda’s outstanding ADSs does this sale represent?

Less than 0.01% of the 123,490,548 ADSs outstanding.

Where will the TAK ADSs be sold and through which broker?

They are slated for sale on the NYSE via Interactive Brokers LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2025 - 06:26 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002009368
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number	001-38757
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo JAPAN 103-8668
Phone	81-3-3278-2306
Name of Person for Whose Account the Securities are To Be Sold	Elaine Mary Shannon
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Global Quality Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	4477	69035.34	123490548	07/09/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2025	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			14516	07/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	07/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Elaine Mary Shannon
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)